Kiyo-Aki Ishii

Kiyo-Aki Ishii

Auto-generated profile, based on publicly available information

Kiyo-Aki Ishii

Department of Endocrinology and Metabolism, Kanazawa University Graduate School of Medical Sciences , Kanazawa 920-8640

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2012 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
YFYuri Fujimoto
Yuri Fujimoto
Yoshimi NakagawaYoshimi Nakagawa
Yoshimi Nakagawa
ASAkiko Shingyouchi
Akiko Shingyouchi
NTNaoko Tokushige
Naoko Tokushige
NNNoriko Nakanishi
Noriko Nakanishi
HSHitoshi Shimano
Hitoshi Shimano

6 July 2007 in Journal of Neuroendocrinology
Verified
Journal Article
Closed access
PDF file
TFT. Fukuda
T. Fukuda
KIK. Ishii
K. Ishii
TNT. Nanmoku
T. Nanmoku
KIK. Isobe
K. Isobe
YKYasuhiko Kawakami
Yasuhiko Kawakami
KTK. Takekoshi
K. Takekoshi

1 February 2024 in The American Journal of Pathology
Verified
Journal Article
Open access
TATuerdiguli Abuduyimiti
Tuerdiguli Abuduyimiti
HGHisanori Goto
Hisanori Goto
KKKumi Kimura
Kumi Kimura
YOYu Oshima
Yu Oshima
RTRyota Tanida
Ryota Tanida
TTToshinari Takamura
Toshinari Takamura
Glucose lowering independently reduces liver fibrosis in human nonalcoholic fatty liver disease. This study investigated the impact of diabetes on steatohepatitis and established a novel mouse model for diabetic steatohepatitis. Male C57BL/6J mice were fed a 60% high-fat diet (HFD) and injected with carbon tetrachloride (CCl4) and streptozotocin (STZ) to induce diabetes. The HFD+CCl4+STZ group showed more severe liver steatosis, hepatocyte ballooning, and regenerative nodules compared with other groups. Diabetes up-regulated inflammatory cytokine-associated genes and increased the M1/M2 macrophage ratios in the liver. Single-cell RNA sequencing analysis of nonparenchymal cells in the liver showed that diabetes reduced Kupffer cells and increased bone marrow-derived recruited inflammatory macrophages, such as Ly6Chi-RM. Diabetes globally reduced liver sinusoidal endothelial cells (LSECs). Furthermore, genes related to the receptor for advanced glycation end products (RAGE)/Toll-like receptor 4 (TLR4) were up-regulated in Ly6Chi-RM and LSECs in mice with diabetes, suggesting a possible role of RAGE/TLR4 signaling in the interaction between inflammatory macrophages and LSECs. This study established a novel diabetic steatohepatitis model using a combination of HFD, CCl4, and STZ. Diabetes exacerbated steatosis, hepatocyte ballooning, fibrosis, regenerative nodule formation, and the macrophage M1/M2 ratios triggered by HFD and CCl4. Single-cell RNA sequencing analysis indicated that diabetes activated inflammatory macrophages and impairs LSECs through the RAGE/TLR4 signaling pathway. These findings open avenues for discovering novel therapeutic targets for diabetic steatohepatitis.

1 June 2022 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Closed access
PDF file
KKKyoko Kamoshita
Kyoko Kamoshita
HTHirohiko Tsugane
Hirohiko Tsugane
KIKiyo-Aki Ishii
Kiyo-Aki Ishii
HTHiroaki Takayama
Hiroaki Takayama
XYXingyu Yao
Xingyu Yao
TTToshinari Takamura
Toshinari Takamura
Selenoprotein P (SeP; encoded by SELENOP in humans, Selenop in rodents) is a hepatokine that is upregulated in the liver of humans with type 2 diabetes. Excess SeP contributes to the onset of insulin resistance and various type 2 diabetes-related complications. We have previously reported that the long-chain saturated fatty acid, palmitic acid, upregulates Selenop expression, whereas the polyunsaturated fatty acids (PUFAs) downregulate it in hepatocytes. However, the effect of medium-chain fatty acids (MCFAs) on Selenop is unknown. Here, we report novel mechanisms that underlie the lauric acid-mediated Selenop gene regulation in hepatocytes. Lauric acid upregulated Selenop expression in Hepa1-6 hepatocytes and mice liver. A luciferase promoter assay and computational analysis of transcription factor-binding sites identified the hepatic nuclear factor 4α (HNF4α) binding site in the SELENOP promoter. A chromatin immunoprecipitation (ChIP) assay showed that lauric acid increased the binding of HNF4α to the SELENOP promoter. The knockdown of Hnf4α using siRNA canceled the upregulation of lauric acid-induced Selenop. The lauric acid-induced impairment of Akt phosphorylation brought about by insulin was rescued by the knockdown of either Hnf4α or Selenop. These results provide new insights into the regulation of SeP by fatty acids and suggest that SeP may mediate MCFA-induced hepatic insulin signal reduction. NEW & NOTEWORTHY Lauric acid induces hepatic insulin resistance by upregulating Selenop. These findings caution the metabolic risk of excessive lauric acid intake, especially in people with hepatic insulin resistance associated with type 2 diabetes.

1 June 2023 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Closed access
HAHalimulati Abuduwaili
Halimulati Abuduwaili
KKKyoko Kamoshita
Kyoko Kamoshita
KIKiyo-Aki Ishii
Kiyo-Aki Ishii
KTKenta Takahashi
Kenta Takahashi
TATuerdiguli Abuduyimiti
Tuerdiguli Abuduyimiti
TTToshinari Takamura
Toshinari Takamura
Selenoprotein P (SeP) is a hepatokine that is upregulated in type 2 diabetes and aging and causes signal resistances via reductive stress. Immobilization (IMM) significantly reduced skeletal muscle mass in mice, which was prevented in SeP knockout (KO) mice. IMM-induced Foxos/KLF15-atrogene upregulation was suppressed in the skeletal muscle of KO mice. These findings suggest that SeP-mediated reductive stress is involved in and may be a therapeutic target for physical inactivity-mediated muscle atrophy.

16 September 2025 in Journal of Biological Chemistry
Verified
Journal Article
Open access
CGCynthia M. Galicia-Medina
Cynthia M. Galicia-Medina
HOHein Ko Oo
Hein Ko Oo
TNTakumi Nishiuchi
Takumi Nishiuchi
RTRyota Tanida
Ryota Tanida
TATuerdiguli Abuduyimiti
Tuerdiguli Abuduyimiti
TTToshinari Takamura
Toshinari Takamura
Reversible cysteine post-translational modifications serve as a "switch" for protein structure-function dynamics. Herein, we applied a comprehensive strategy to map the cysteine redoxome by pinpointing over 5,000 oxidized and reduced cysteine residues in the liver of male mice fed either a normal chow diet (NCD) or a high-fat/high-sucrose diet (HFHSD). The global and subcellular distribution of oxidized and reduced cysteine residues remained stable across both diet groups, indicating that HFHSD does not induce widespread shifts in cysteine redox equilibrium. Proteomic analyses revealed that HFHSD upregulates proteins involved in genomic stability, lipid detoxification, and energy regulation, while downregulating those linked to detoxification and metabolic flexibility. Notably, 169 cysteine residues exhibited dynamic redox changes in response to HFHSD, mapping to 35 KEGG pathways central to redox balance and energy homeostasis. Motif and structural analyses demonstrated that the reactivity of cysteine residues sensitive to redox stress is dictated by distinct electrostatic microenvironments and subcellular localization. Cysteine residues sensitive to HFHSD-induced oxidation were enriched in mitochondria and cytosol, and cysteine residues sensitive to HFHSD-induced reduction in extracellular regions. Furthermore, cysteine residues sensitive to HFHSD-induced reduction mainly participate in disulfide bond formation and are exposed to the surface of the protein, suggesting roles as molecular switches in protein function. The current cysteine redoxome strategy broadens the disease-associated proteome landscape and provides potential therapeutic target cysteine residues critical for regulating protein functions and interactions relevant to pathophysiology.